Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, 3775 University Street, Montreal, QC H3A 2B4, Canada.
Industrial Biotechnology Division, National Institute for Biotechnology and Genetic Engineering College, Pakistan Institute of Engineering and Applied Sciences (NIBGE-C, PIEAS), Faisalabad 38000, Pakistan.
Int J Mol Sci. 2022 Oct 21;23(20):12692. doi: 10.3390/ijms232012692.
Metabolic syndrome is a leading medical concern that affects one billion people worldwide. Metabolic syndrome is defined by a clustering of risk factors that predispose an individual to cardiovascular disease, diabetes and stroke. In recent years, the apparent role of the gut microbiota in metabolic syndrome has drawn attention to microbiome-engineered therapeutics. Specifically, lactic acid bacteria (LAB) harbors beneficial metabolic characteristics, including the production of exopolysaccharides and other microbial byproducts. We recently isolated a novel fructophilic lactic acid bacterium (FLAB), strain HBW1, from honeybee gut and found it produces a dextran-type exopolysaccharide (EPS). The objective of this study was to explore the therapeutic potential of the new dextran in relation to metabolic syndrome. Findings revealed the dextran's ability to improve the viability of damaged HT-29 intestinal epithelial cells and exhibit antioxidant properties. In vivo analyses demonstrated reductions in body weight gain and serum cholesterol levels in mice supplemented with the dextran, compared to control (5% and 17.2%, respectively). Additionally, blood glucose levels decreased by 16.26% following dextran supplementation, while increasing by 15.2% in non-treated mice. Overall, this study displays biotherapeutic potential of a novel EPS to improve metabolic syndrome and its individual components, warranting further investigation.
代谢综合征是一个主要的医学关注点，影响着全球十亿人口。代谢综合征的定义是一系列风险因素的聚集，使个体易患心血管疾病、糖尿病和中风。近年来，肠道微生物群在代谢综合征中的明显作用引起了人们对微生物组工程治疗学的关注。具体来说，乳酸菌（LAB）具有有益的代谢特性，包括产生胞外多糖和其他微生物副产物。我们最近从蜜蜂肠道中分离到一种新型嗜果糖乳酸菌（FLAB），菌株 HBW1，并发现它产生一种葡聚糖型胞外多糖（EPS）。本研究旨在探索新型葡聚糖在代谢综合征方面的治疗潜力。研究结果表明，葡聚糖能够提高受损 HT-29 肠上皮细胞的活力，并表现出抗氧化特性。体内分析表明，与对照组相比，补充葡聚糖的小鼠体重增加和血清胆固醇水平分别降低了 5%和 17.2%。此外，葡聚糖补充后血糖水平降低了 16.26%，而未治疗的小鼠血糖水平升高了 15.2%。总的来说，这项研究显示了一种新型 EPS 改善代谢综合征及其各个成分的生物治疗潜力，值得进一步研究。
